Incidence Of Neuregulin1 (Nrg1) Gene Fusions Across Tumor Types

12084Background: NRG1 gene fusions are an emerging potential therapeutic target in non-small cell lung cancer (NSCLC). NRG1 is a ligand for the HER3 tyrosine kinase and NRG1 fusions can activate oncogenic HER2/HER3 and PI3K-AKT signaling. The pan-ErbB inhibitor afatinib has been associated with durable response in patients with NRG1+ lung adenocarcinoma. NRG1 fusions and the specific fusion partners have not been well characterized across different tumor types. Methods: Tumor samples submitted for profiling between 01/16 - 01/18 at a CLIA-certified genomics laboratory (Caris Life Sciences, Phoenix, AZ) were assayed with anchored multiplex PCR for targeted RNA sequencing with the ArcherDX fusion assay (Boulder, CO). Novel isoforms and fusions with high reads (defined as u003e 10% of total reads), high confidence after bioinformatics filtering and considered in-frame are included in this analysis. Results: In a cohort of 14,150 tumors successfully assayed, 31 cases (0.2%) harbored an NRG1 fusion. The incidence ...